文献速递癫痫神经重症与神经感染

癫痫持续状态病因学检查的诊断率与治疗影响:ICTAL登记研究

Diagnostic Yield and Therapeutic Impact of Etiologic Investigations After Status Epilepticus: Insights From the ICTAL Registry.
PubMed 文献 · Neurology · 2026-09-21

该前瞻性多中心队列研究基于法国ICTAL登记,纳入1123例成人癫痫持续状态患者,按验前概率分层评估病因学检查的诊断率与治疗影响。结果显示一线检查确认率为8.5%-44.5%,重分类率为22.1%-35.1%,脑MRI管理改变最高达58.3%,提示分层诊断策略可优化病因识别。

要点

  • 毒物筛查在酒精/中毒/医源性病因中确认率最高(44.5%)。
  • 脑MRI在非感染性脑炎中重分类率最高(35.1%),管理改变达58.3%。
  • 诊断率与治疗影响受验前临床概率强烈影响,建议分层检查。

核心结论

  • 癫痫持续状态病因学检查的诊断率和治疗影响受验前临床概率强烈影响,分层诊断策略可能优化病因识别并指导及时靶向干预。

研究设计与样本

  • 基于ICTAL登记的前瞻性多中心队列研究,法国26个大学附属ICU参与(2018-2025年),纳入1123例成人癫痫持续状态患者,执行预定义诊断方案。

主要发现

  • 在高验前概率分层中,一线检查确认疑似病因为8.5%-44.5%,重分类为22.1%-35.1%。
  • 确认率最高为毒物筛查在酒精/中毒/医源性病因(44.5%)、抗癫痫药物检测在诱发因素(44.0%)、副肿瘤/自身免疫检查在非感染性脑炎(40.0%)。
  • 脑MRI重分类率为27.8%-35.1%,在非感染性脑炎最高(35.1%);脑CT重分类率为22.1%-27.9%。
  • 管理改变最常见于脑MRI(最高58.3%)、脑CT(最高56.9%)、腰椎穿刺(39.4%)、副肿瘤/自身免疫检查(33.3%)和抗癫痫药物检测(最高35.1%)。

关键数值与推荐

  • 毒物筛查在酒精/中毒/医源性病因中确认率44.5%,在代谢表现中重分类率32.4%。
  • 抗癫痫药物检测在诱发因素中确认率44.0%,管理改变最高35.1%。
  • 副肿瘤/自身免疫检查在非感染性脑炎中确认率40.0%,管理改变33.3%。
  • 脑CT在血管性病因确认率28.0%、脑肿瘤27.7%,管理改变最高56.9%。
  • 实验室检查在代谢性病因确认率21.4%;腰椎穿刺在中枢神经系统感染确认率17.2%,管理改变39.4%。

临床怎么用

  • 对癫痫持续状态患者应依据验前临床概率分层选择病因学检查,以提高诊断效率。
  • 高怀疑非感染性脑炎时优先脑MRI,其重分类率和管理改变率较高。
  • 怀疑酒精/中毒/医源性病因时毒物筛查确认率高,可指导治疗调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Status epilepticus (SE) is a critical neurologic emergency requiring prompt symptomatic and etiologic treatment. However, the diagnostic yield of etiologic investigations remains poorly characterized. We aimed to evaluate the diagnostic yield and therapeutic impact of etiologic investigations in SE, using pretest probability strata. METHODS: This prospective multicenter cohort study based on the ICTAL registry was conducted in 26 university-affiliated intensive care units (ICUs) in France (2018-2025). All adults (≥18 years) admitted for SE were included. Participants underwent a predefined diagnostic protocol including brain imaging (CT scan/MRI), laboratory investigations, lumbar puncture, toxicology screening, antiseizure medication (ASM) assays, and paraneoplastic/autoimmune disease workup. The primary outcome was the diagnostic yield of each test, defined as confirmation, codiagnosis, or reclassification of SE etiology. The secondary outcome was management changes directly attributable to test results. RESULTS: Among 1,123 patients (64% male; median age 60 years), SE was motor-predominant in 90%. Across high pretest probability strata, first-line investigations confirmed the suspected etiology in 8.5%-44.5% of cases and reclassified it in 22.1%-35.1%. Confirmation rates were the highest for toxicology screening in alcohol/toxic/iatrogenic causes (44.5%), ASM assays in precipitating factors (44.0%), paraneoplastic/autoimmune workup in noninfectious encephalitis (40.0%), brain CT in vascular causes (28.0%) and brain tumor (27.7%), laboratory investigations in metabolic causes (21.4%), and lumbar puncture in CNS infection (17.2%). Reclassification was most evident for brain MRI (27.8%-35.1%) across CNS infection, metabolic, noninfectious encephalitis, and sequelae strata, with the highest rate in noninfectious encephalitis (35.1%); brain CT contributed similarly (22.1%-27.9%). Toxicology screening reclassified 32.4% of high pretest probability metabolic presentations. Management changes were most frequent following brain MRI (up to 58.3%), brain CT (up to 56.9%), lumbar puncture (39.4%), paraneoplastic/autoimmune workup (33.3%), and ASM assays (up to 35.1%). DISCUSSION: Diagnostic yield and therapeutic impact of investigations in SE are strongly influenced by pretest clinical probability. Stratified diagnostic strategies may optimize etiologic identification and guide timely, targeted interventions. TRIAL REGISTRATION INFORMATION: The study is registered with ClinicalTrials.gov, number NCT03457831.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Repplinger S, Chelly J, Lesieur O, et al. Diagnostic Yield and Therapeutic Impact of Etiologic Investigations After Status Epilepticus: Insights From the ICTAL Registry. Neurology. 2026. PMID: 42766827. doi:10.1212/WNL.0000000000218544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。